Dateline City:
KENILWORTH, N.J.
KEYTRUDA Also Approved for Second-Line Treatment of Patients with Advanced NSCLC Whose Tumors Express PD-L1
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that KEYTRUDA (pembrolizumab), the companys
anti-PD-1 therapy, has been approved in Japan for the treatment of
certain patients with PD-L1-positive unresectable advanced/recurrent
non-small cell lung cancer (NSCLC) in the first- and second-line
treatment settings at a fixed dose of 200 mg every three weeks. MSD will
manufacture and market KEYTRUDA in Japan and will promote it with Taiho
Pharmaceutical Co., Ltd.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
@Merck
read more